NantHealth® and Northwest Fire Fighters Benefits Trust (NWFFT) Join Forces to Provide GPS Cancer® and Liquid GPS to Trust Covered Members
“Firefighters risk their lives every day for public safety, often
exposing themselves to carcinogens. Cancer rates are much higher in
firefighters than the average population, and each NWFFT covered member
deserve to have the most innovative and comprehensive tools available to
fight this disease. Ensuring access to GPS Cancer and Liquid GPS tests
GPS Cancer® offer a comprehensive molecular profile providing precision insights that include the analysis of a patient’s tumor genome compared to their normal genome and uses DNA sequencing (20,000 genes, 3 billion base pairs) with RNA expression (over 200,000 transcripts) unique to each patient. In addition, pharmacogenomic analysis is provided that may indicate genetic influences to certain cancer treatment drugs. This robust test report provides more information that may guide oncologists to eliminate potential false positive drug targets and tailor treatment decisions for the best possible outcomes based on a patient’s unique profile.
Liquid GPS is a blood-based molecular test that allows oncologists to analyze specific mutational targets when tumor tissue is not available with cfDNA and cfRNA, and provides the ability to monitor mutational response to treatment evaluating quantitative cfRNA.
“Cancer is impacting the lives of firefighters at a greater rate than
we’ve seen in the past and as compared with the general population in
the U.S., making it crucial to provide them with the most advanced
healthcare strategies and technology available,” said Dr. Sandeep
“Bobby” Reddy, Chief Medical Officer of
Consultants at DiMartino